The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
Three new medicines sailed through the review of a key health ministry panel on March 6 to close in on Japanese regulatory approval, including Takeda Pharmaceutical’s ileal bile acid transporter (IBAT) inhibitor maralixibat, known as Livmarli overseas. The Pharmaceutical Affairs…
To read the full story
Related Article
- Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
March 28, 2025
- Izervay Filed for Conditional Approval in Japan: Astellas
February 6, 2025
- BMS Files Hypertrophic Cardiomyopathy Drug in Japan
July 18, 2024
- Takeda Files Alagille Syndrome Drug Maralixibat in Japan
June 28, 2024
- Towa Files NDA for Rivastigmine Twice Weekly Transdermal Patch in Japan
June 10, 2024
- Janssen Files Tremfya for Ulcerative Colitis in Japan
April 26, 2024
REGULATORY
- Japan Weighs Scrapping “Spillover” Rule in Shift from Draft Reform Outline
December 24, 2025
- Heparinoid, Allergy Drugs among OTC-Like Meds Up for Special Charge Rule
December 24, 2025
- Japan Hands Out Orphan Designation to 11 Drugs
December 24, 2025
- Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
- Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
December 23, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…